Literature DB >> 3133400

Artificial factor VIII deficient plasma: preparation using monoclonal antibodies and its use in one stage coagulation assays.

V S Hornsey1, Y G Waterston, C V Prowse.   

Abstract

Monoclonal antibodies to factor VIII antigen (VIII:Ag) and von Willebrand factor (vWf:Ag) were immobilised on Sephacryl S-1000 and tested for their ability to deplete normal human citrated plasma of factor VIII. A combination of two antibodies to VIII:Ag and one antibody to vWf:Ag was required to produce plasma containing less than 0.01 IU/ml. Its performance in the one stage coagulation assay of VIII:C was equivalent to that of congenital VIII deficient plasma for the assay of normal and haemophilic plasma and factor VIII concentrates. Storage of freeze dried aliquots of this product at -20 degrees C, +4 degrees C, and 37 degrees C showed that it could be used as a substrate for at least six months when stored at temperatures +4 degrees C and below.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3133400      PMCID: PMC1141513          DOI: 10.1136/jcp.41.5.562

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

1.  A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma.

Authors:  R M HARDISTY; J C MACPHERSON
Journal:  Thromb Diath Haemorrh       Date:  1962-05-15

2.  Factor VIII deficient plasma for laboratory tests prepared from normal plasma and a human antibody.

Authors:  T Exner; K A Rickard; S Speers
Journal:  Haemostasis       Date:  1977

3.  Preparation of factor VIII-deficient plasma by immunoadsorption.

Authors:  M Furlan; R Felix; E A Beck
Journal:  Vox Sang       Date:  1979       Impact factor: 2.144

4.  Assay of factor VIII:C with a chromogenic substrate.

Authors:  S Rosén
Journal:  Scand J Haematol Suppl       Date:  1984

5.  Immunodepletion of human plasma factor VIII.

Authors:  F Ofosu; K Cassidy; M A Blajchman; J Hirsh
Journal:  Blood       Date:  1980-10       Impact factor: 22.113

6.  Influence of high molecular weight factor VIII on the measurement of low molecular weight factor VIII procoagulant in different assay systems.

Authors:  W Muntean; W E Hathaway; R R Montgomery
Journal:  Br J Haematol       Date:  1982-08       Impact factor: 6.998

7.  A new approach (cyano-transfer) for cyanogen bromide activation of Sepharose at neutral pH, which yields activated resins, free of interfering nitrogen derivatives.

Authors:  J Kohn; M Wilchek
Journal:  Biochem Biophys Res Commun       Date:  1982-08       Impact factor: 3.575

8.  Evidence that von Willebrand factor is not required for the clotting of plasma in the presence of platelets and kaolin (Hardisty-Hutton test).

Authors:  J McPherson; M E Soberano; C Macdonald; M B Zucker
Journal:  Thromb Haemost       Date:  1984-04-30       Impact factor: 5.249

9.  A convenient replacement for cyanogen bromide-activated solid phases in immunoradiometric assays.

Authors:  J F Wright; W M Hunter
Journal:  J Immunol Methods       Date:  1982       Impact factor: 2.303

10.  Enhancement of factor VIII-von Willebrand factor ristocetin cofactor activity by monoclonal antibodies.

Authors:  V Hornsey; L R Micklem; M C McCann; K James; J Dawes; D B McClelland; C V Prowse
Journal:  Thromb Haemost       Date:  1985-08-30       Impact factor: 5.249

View more
  3 in total

1.  Production of plasma selectively depleted in fibrinogen by affinity chromatography.

Authors:  C F Hirst; K J Stevenson
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

2.  Acquired coagulant factor VIII deficiency induced by Bacillus anthracis lethal toxin in mice.

Authors:  Der-Shan Sun; Po-Chien Lee; Jyh-Hwa Kau; Yung-Luen Shih; Hsin-Hsien Huang; Chen-Ru Li; Chin-Cheng Lee; Yu-Ping Wu; Kuo-Ching Chen; Hsin-Hou Chang
Journal:  Virulence       Date:  2015-04-23       Impact factor: 5.882

3.  GNG13 Is a Potential Marker of the State of Health of Alzheimer's Disease Patients' Cerebellum.

Authors:  Cristina Sanfilippo; Giuseppe Musumeci; Maria Kazakova; Venera Mazzone; Paola Castrogiovanni; Rosa Imbesi; Michelino Di Rosa
Journal:  J Mol Neurosci       Date:  2020-10-15       Impact factor: 3.444

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.